Donald L Siegel

This inventor holds 26 USPTO granted patents and 8 published patent applications and 1 EPO patent, primarily in Cancer Immunotherapy. Top assignees: University of Pennsylvania, Scripps Research Institute, Novartis Ag. Active years: 1999-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Donald L Siegel. Retrieved from https://idiyas.com/inventor/donald-l-siegel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 8)

% Patents Active = 80.8

EPO Patents = 1 (Patent Applications = 5)

Average Co-Inventor Count = 1.7

ph-index = 5

Forward Citations = 75(Granted Patents)

Location History:

Hatboro, PA (US) (1999 - 2012)
Philadelphia, PA (US) (2017)
Landsdale, PA (US) (2023)
Lansdale, PA (US) (2010 - 2024)

Company Filing History:

26 out of 2,659

University of Pennsylvania

patents

4 out of 1,208

Scripps Research Institute

University of Florida Research Foundation Inc.

where one patent can have more than one assignee

Years Active: 1999-2025

Loading Chart...

Areas of Expertise:

Chimeric Antigen Receptors

Monoclonal Antibodies

Tumor-Related Antigens

Phage Display

Autoantibodies

Drug Delivery

Diagnostic Reagents

Cell Sorting

Anti-Platelet Antibodies

GDNF Family

CTLA-4

Rh(D)-Binding Proteins

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12410234 - Compositions and methods for retrieving tumor-related antibodies and antigens (2025-09-09),

2. 12281167 - Humanized anti-GDNF family alpha-receptor 4 (GRF-alpha-4) antibodies and chimeric antigen receptors (CARs) (2025-04-21),

3. 12110331 - Canine monoclonal antibodies against canine cytotoxic T lymphocyte associated protein 4 (CTLA-4) (2024-10-08),

4. 11970525 - Treatment of cancer using GFR alpha-4 chimeric antigen receptor (2024-04-30),

5. 11802159 - Humanized anti-GDNF family alpha-receptor 4 (GRF-alpha-4) antibodies and chimeric antigen receptors (CARs) (2023-10-31),

6. 11629198 - Fusion proteins and antibodies targeting human red blood cell antigens (2023-04-18),

7. 11597778 - Human monoclonal autoantibodies to ADAMTS13 and uses thereof (2023-03-07),

8. 11078285 - Anti-TEM1 antibodies and uses thereof (2021-08-03),

9. 10851149 - Treatment of cancer using GFR α-4 chimeric antigen receptor (2020-12-01),

10. 10160809 - Anti-TEM1 antibodies and uses thereof (2018-12-25),

11. 9658224 - Phage particle diagnostic reagents (2017-05-23),

12. 9556272 - Anti-TEM1 antibodies and uses thereof (2017-01-31),

13. 8846867 - Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies (2014-09-30),

14. 8623594 - Methods for isolation of antibody binding to cells (2014-01-07),

15. 8617805 - Compositions, methods and kits for detection of an antigen on a cell and in a biological mixture (2013-12-31),

Title: Donald L. Siegel: Innovator in Canine Biomedical Research

Introduction

Donald L. Siegel is an accomplished inventor based in Hatboro, PA, with a remarkable portfolio of 24 patents. His work primarily revolves around advancements in canine biomedical research, with a focus on innovative therapeutic approaches.

Latest Patents

Among his latest patents is the invention of canine monoclonal antibodies against canine cytotoxic T lymphocyte associated protein 4 (CTLA-4). This invention pertains to canine antibodies, binding polypeptides, and single-chain variable fragments (scFvs) specifically targeting CTLA-4, a crucial component in immune response regulation. Another significant patent details the treatment of cancer using GFR alpha-4 chimeric antigen receptor. This innovation addresses compositions and methods for treating various diseases associated with the Glycosyl-phosphatidylinositol (GPI)-linked GDNF family α-receptor 4 (GFRα4).

Career Highlights

Donald L. Siegel has had a noteworthy career, significantly impacting the field of veterinary medicine through his innovative research. His contributions are vital for advancing medical treatments for dogs, enhancing the quality of healthcare in veterinary practices.

Collaborations

Throughout his career, Siegel has collaborated with several notable individuals, including John R. Stanley and Vijay Bhoj. Additionally, he has been associated with reputable institutions such as the University of Pennsylvania and The Scripps Research Institute, further broadening the scope and impact of his research endeavors.

Conclusion

In conclusion, Donald L. Siegel stands out as a notable inventor in the field of canine biomedical research. With his extensive patent portfolio and impactful collaborations, he continues to make significant strides in advancing veterinary therapeutics. His work not only paves the way for innovative treatments but also contributes to the overall improvement of animal health and welfare.

Profile summary based on public USPTO records.